DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on November 28, 2006; DOI: 10.1124/dmd.106.011569


0090-9556/07/3502-293-301$20.00
DMD 35:293-301, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.011569v1
35/2/293    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, H. S.
Right arrow Articles by Houston, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, H. S.
Right arrow Articles by Houston, J. B.

Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance

Hayley S. Brown, Michael Griffin, and J. Brian Houston

Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom

Human liver microsomes have typically resulted in marked underprediction of in vivo human intrinsic clearance (CLint); therefore, the utility of cryopreserved hepatocytes as an alternative in vitro system has become an important issue. In this study, 10 compounds (tolbutamide, diclofenac, S-warfarin, S-mephenytoin, dextromethorphan, bufuralol, quinidine, nifedipine, testosterone, and terfenadine) were selected as substrate probes for CYP2C9, 2C19, 2D6, and 3A4, and the kinetics of metabolite formation (n = 14 pathways) were investigated in three individual lots of cryopreserved hepatocytes and in a pool of human liver microsomes. For the majority of the compounds, lower unbound KM or S50 values were observed in hepatocytes compared with microsomes, on average by 50% over a 200-fold range (0.5–140 µM). Expressed on an equivalent liver weight basis, a good correlation between microsomal and hepatocyte Vmax values was observed for most pathways greater than 5 orders of magnitude (0.16–216 nmol/min/g liver). Unbound hepatocyte CLint (CLint,u) values, when scaled to the whole liver (range 0.38–4000 ml/min/kg), were on average 2.5-fold higher than microsomal CLint,u values, with the exception of tolbutamide and diclofenac, for which lower hepatocellular CLint,u values were observed. Hepatocyte predicted CLint values were compared with human in vivo CLint values, and to supplement our data, in vitro data from cryopreserved hepatocytes were collated from four other published sources. These data show that for 37 drugs, there is, on average, a 4.5-fold under-prediction of the in vivo CLint using cryopreserved hepatocytes, representing a significant reduction in prediction bias compared with human microsomes.


Address correspondence to: J. Brian Houston, Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, M13 9PL, UK. E-mail: brian.houston{at}manchester.ac.uk




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
P. J. Kilford, M. Gertz, J. B. Houston, and A. Galetin
Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data
Drug Metab. Dispos., July 1, 2008; 36(7): 1194 - 1197.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. J. Parker and J. B. Houston
Rate-Limiting Steps in Hepatic Drug Clearance: Comparison of Hepatocellular Uptake and Metabolism with Microsomal Metabolism of Saquinavir, Nelfinavir, and Ritonavir
Drug Metab. Dispos., July 1, 2008; 36(7): 1375 - 1384.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Rowland, D. J. Elliot, K. M. Knights, P. I. Mackenzie, and J. O. Miners
The "Albumin Effect" and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9
Drug Metab. Dispos., May 1, 2008; 36(5): 870 - 877.
[Abstract] [Full Text] [PDF]


Home page
J Biomol ScreenHome page
Cheng Li, Tongtong Liu, Xiaoming Cui, A. S. Uss, and K.-C. Cheng
Development of In Vitro Pharmacokinetic Screens Using Caco-2, Human Hepatocyte, and Caco-2/Human Hepatocyte Hybrid Systems for the Prediction of Oral Bioavailability in Humans
J Biomol Screen, December 1, 2007; 12(8): 1084 - 1091.
[Abstract] [PDF]


Home page
Drug Metab. Dispos.Home page
H. S. Brown, A. Chadwick, and J. B. Houston
Use of Isolated Hepatocyte Preparations for Cytochrome P450 Inhibition Studies: Comparison with Microsomes for Ki Determination
Drug Metab. Dispos., November 1, 2007; 35(11): 2119 - 2126.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
B. Karanam, M. Madeira, S. Bradley, L. Wenning, R. Desai, E. Soli, D. Schenk, A. Jones, B. Dean, G. Doss, et al.
Absorption, Metabolism, and Excretion of [14C]MK-0524, a Prostaglandin D2 Receptor Antagonist, in Humans
Drug Metab. Dispos., July 1, 2007; 35(7): 1196 - 1202.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.